Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Marky1on Sep 09, 2020 5:30pm

190 Views

Post# 31530695

RE:RE:RE:RE:Dr. John Wallace

Nice to hear from you Magic! Missed your comments...always great reading...No, I am still very positive on ATE....I believe in the chemistry, the H2S technology, in management...but...i was extremely disappointed by the June PR bringing to SP from .89$ to under .60$....I feel that they really mucked it up....They should, I think, just left off the 150mg dosage...200 mg and 250mg were that's all that was needed..why bring something that was not statistically significant into the equation..Hopefully the new NY company, Stern, will do a better job aimed at institutional, retail audience
IMHO...
take care folks
Jean Marc

Bullboard Posts

Changing Europe’s dependency on HREE from China